Treatments using supplements containing epigallocatechin-3-gallate (EGCG) – a putative DYRK1A inhibitor – have been reported to improve cognitive performance in DS mouse models and in some measures in clinical trials (De la Torre et al., 2014, 2016; Pons-Espinal et al., 2013; Souchet et al., 2019). The gene discussed is DYRK1A; the disease is Dravet syndrome.